Friday, 16 October 2026European Markets

CAFOM Stock Was 9.05% Up On Tuesday

Loading stream...

(vianews) - the market ended the session with cafom (cafo.pa) jumping 9.05% to €9.40 on tuesday while cac 40 fell 0.32% to €7,426.62.

cafom's last close was €8.62, 28.46% under its 52-week high of €12.05.

about cafom

centrale d'achat française pour l'outre-mer société anonyme provides home furnishing products in south-east asia, south america, europe, and middle east. the company offers household appliance products and services under darty; home equipment under but; design manufacturing under habitat; natural and wellness products under the nature & discoveries; furniture, decoration, and appliances under but cosy; and musical instruments under the music & sound brands in guadeloupe, french guiana, martinique, saint-martin, reunion island, and new caledonia. it also operates vente-unique.com, a b2c platform that engages in the online sale of furniture for individuals; and directlowcost.com that supplies furniture and decoration products for distribution professionals. the company was founded in 1985 and is based in paris, france.

earnings per share

as for profitability, cafom has a trailing twelve months eps of €0.97.

pe ratio

cafom has a trailing twelve months price to earnings ratio of 9.69. meaning, the purchaser of the share is investing €9.69 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.66%.

volatility

cafom's last week, last month's, and last quarter's current intraday variation average was a negative 1.62%, a negative 0.46%, and a positive 1.08%.

cafom's highest amplitude of average volatility was 2.28% (last week), 1.45% (last month), and 1.08% (last quarter).

yearly top and bottom value

cafom's stock is valued at €9.40 at 21:30 est, way below its 52-week high of €12.05 and way higher than its 52-week low of €7.70.

more news about cafom (cafo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com